Insider Selling: Knight Therapeutics Inc. (TSE:GUD) Director Sells C$118,710.00 in Stock

Knight Therapeutics Inc. (TSE:GUDGet Free Report) Director Robert Nathaniel Lande sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of C$5.94, for a total transaction of C$118,710.00.

Robert Nathaniel Lande also recently made the following trade(s):

  • On Wednesday, May 29th, Robert Nathaniel Lande sold 15,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.91, for a total transaction of C$88,600.50.

Knight Therapeutics Trading Down 0.7 %

Shares of GUD opened at C$5.70 on Friday. The firm has a market cap of C$577.87 million, a price-to-earnings ratio of -35.63, a PEG ratio of -1,013.50 and a beta of 0.46. The company has a debt-to-equity ratio of 9.20, a quick ratio of 1.79 and a current ratio of 3.34. Knight Therapeutics Inc. has a fifty-two week low of C$4.35 and a fifty-two week high of C$6.22. The firm has a 50 day moving average price of C$5.87 and a 200-day moving average price of C$5.56.

Knight Therapeutics (TSE:GUDGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported C($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.06). The business had revenue of C$86.60 million during the quarter, compared to the consensus estimate of C$80.27 million. Knight Therapeutics had a negative return on equity of 2.21% and a negative net margin of 5.25%. As a group, equities research analysts forecast that Knight Therapeutics Inc. will post 0.0303448 earnings per share for the current year.

Analyst Upgrades and Downgrades

GUD has been the subject of several research analyst reports. Stifel Nicolaus lifted their target price on shares of Knight Therapeutics from C$5.40 to C$5.75 in a research report on Friday, May 10th. Royal Bank of Canada lifted their target price on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Finally, Raymond James lifted their target price on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the company an “outperform” rating in a research report on Wednesday, March 6th.

View Our Latest Stock Analysis on GUD

About Knight Therapeutics

(Get Free Report)

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

Read More

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.